Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food Intake on SPH3127 PK in Healthy Chinese Subjects
NCT03249753Phase 1Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sitokiren in hypertension (HTN) (2 arms), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Plasma area under curve (AUC) (0-infinity), Plasma Maximum Concentration and 2 more. Started Sep 2017; status: completed.
02
Drugs
sitokiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03249753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249753.